November 19, 2010

HELIX BIOPHARMA CORP. PROVIDES UPDATE ON PHASE II/III IND APPLICATION FOR TOPICAL INTERFERON ALPHA-2B (PDF)

AURORA, Ontario, November 19, 2010 – Helix BioPharma Corp. (TSX, NYSE Amex, FSE: “HBP”), a biopharmaceutical
company developing drug candidates for the prevention and treatment of cancer, today announced that it has received verbal notice from the United States Food and Drug Administration (“FDA”) that its pending Topical Interferon Alpha-2b Phase II/III investigational new drug (“IND”) application has been placed on “clinical hold”.